SAN DIEGO, July 28 /PRNewswire-FirstCall/ -- Ardea Biosciences, Inc. (Nasdaq: RDEA) today announced that data will be presented on RDEA806, the Company's novel investigational non-nucleoside reverse transcriptase inhibitor (NNRTI) for patients with human immunodeficiency virus (HIV) at the 48th Annual ICAAC/IDSA 46th Annual Meeting in Washington, DC on October 25-28, 2008.
Dr. Graeme Moyle, Director of HIV Research, Chelsea and Westminster
Hospital, will present pharmacokinetic and pharmacodynamic data from the
Phase 2a proof-of-concept monotherapy study of RDEA806, during an oral
presentation on October 26, 2008. Additionally, a poster will be presented
on the resistance data for RDEA806 on the same day.
The presentation details are as follows:
Control Number: 4707
Title: Antiretroviral Therapy
Session Type: Slide Session
Presentation Title: RDEA806, a Novel HIV Non-Nucleoside Reverse
Transcriptase Inhibitor, Shows Positive Outcome in Treatment of Naive HIV
Session Day / Time: Sunday, October 26, 2008, 8:30am EDT
Presentation Time: 9:00am - 9:15am EDT
Location: Independence A (Grand Hyatt)
Control Number: 4643
Title: Antiretroviral Resistance and HIV Diagnostics
Session Type: Poster Session
Presentation Title: Resistance to RDEA806 Requires Multiple Mutations
Which Have Limited Cross-resistance to Other NNRTIs .
Session Day / Time: Sunday, October 26, 2008 11:15am EDT
About Ardea Biosciences, Inc.
Ardea Biosciences, Inc., of San Diego, California, is a biotechnology
company focused on the discovery and development of small-molecule
therapeutics for the treatment of HIV, cancer and inflammatory dis
|SOURCE Ardea Biosciences, Inc.|
Copyright©2008 PR Newswire.
All rights reserved